Medherant Signs Agreement With Leading Japanese Transdermal Patch Company For Evaluation Of Its TEPI Patch Drug Delivery System

Published: Sep 27, 2017

COVENTRY, England--(BUSINESS WIRE)--Medherant, a leader in next-generation transdermal drug delivery, has signed an agreement with a Japanese transdermal patch company (“the company”), one of the world’s largest patch developers and manufacturers, to evaluate the potential of its TEPI Patch® technology to deliver a drug provided by the company.

“We have developed a very good relationship with the company and are delighted to begin this feasibility study. We are confident that we will rapidly create a comprehensive data set that will demonstrate the merits of our TEPI Patch® technology.”

Medherant will apply its proprietary high-throughput system for skin permeation studies to rapidly evaluate a range of potential formulations of the drug provided by the company. A successful outcome could lead to the company licensing the TEPI Patch® technology to develop a product for a market where sales are currently > $1bn and patient numbers are rising. The delivery of the drug via a patch is technically challenging but Medherant believes its technology will provide the solution the company needs.

TEPI Patches® are formulated by mixing the drug with a novel adhesive. The adhesive enables high drug loading, allowing lower potency drugs to be delivered successfully and providing the opportunity to include excipients to facilitate movement of the drug through the skin. Significantly, TEPI Patch® sticks to the skin better than others tested, this is a critical factor in ensuring delivery of the full dose and without leaving a dark residue at the edge.

Nigel Davis, CEO, Medherant, said “We have developed a very good relationship with the company and are delighted to begin this feasibility study. We are confident that we will rapidly create a comprehensive data set that will demonstrate the merits of our TEPI Patch® technology.”

Ends

About Medherant

Medherant Ltd is a leading developer of next-generation transdermal drug delivery patches. Its TEPI Patch® technology can:

  • deliver a wider range of drugs
  • provide a higher dose
  • provide a better patient experience
    • adheres to the skin for longer
    • less painful to remove
    • does not mark the skin

Medherant is developing products it intends to license prior to commercialisation. The first product is an ibuprofen TEPI Patch®. Medherant also runs feasibility studies that give companies the opportunity to see the benefits of delivering their drugs using the TEPI Patch® technology.

Medherant
Nigel Davis, CEO
E: N.Davis@medherant.co.uk
T: +44 (0)24 7632 3060
or
Media Relations, Sciad Communications
Deborah Cockerill / Emma Pickup
E: Medherant@sciad.com
T: +44 (0)20 7470 8801

Back to news